It was good. Never visited a Scientific Update conference, but will get it on my priority list. Very good – like the set-up, flow and topics. Very interested in process development.
It was good. Never visited a Scientific Update conference, but will get it on my priority list. Very good – like the set-up, flow and topics. Very interested in process development.
It was good. Never visited a Scientific Update conference, but will get it on my priority list. Very good – like the set-up, flow and topics. Very interested in process development.
Last month I posted a scheme for the synthesis of a late-stage intermediate towards AZD9833, a compound identified by AstraZeneca as a selective estrogen receptor degrader (SERD) and antagonist that is currently in phase 2b clinical trials for the treatment of ER+ breast cancer. I asked if you could identify reagents or intermediates A-C. Below are the answers! You can read more here in the full reference: J. Scott et al, J. Med. Chem. 2020, 63, 14530–14559
New Years Resolutions: What Are Your Professional Aims for 2025? Is CPD Training on the Agenda? As we step into 2025, many of us will take time to reflect on our professional achievements and set ambitious goals for the coming year. Whether you’re a seasoned chemist or just embarking on your career, one thing…
Peptide drugs have very recently been in the limelight because of the success of the Novo Nordisk blockbuster GLP-1 agonist Semaglutide (Ozempic, Figure 1).1 GLP-1 agonists primarily stimulate glucose- dependent insulin release from pancreatic islets, underpinning its use in the treatment of diabetes. An add-on, equally important, function is the slowing of gastric emptying- reducing…
Bec's Bitesized Blog - Are you in the iPRD Industrial club? Last week, I had the pleasure of attending the Institute of Process Research and Development (iPRD) Industrial Club's autumn meeting in Leeds, a city that holds a special place in my heart, having spent several happy years there during my PhD studies. For those…
